Home » Stocks » Novo Nordisk A/S

Novo Nordisk A/S (NVO)

Stock Price: $65.77 USD -0.57 (-0.86%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 117.93B
Revenue (ttm) 20.13B
Net Income (ttm) 6.59B
Shares Out 2.33B
EPS (ttm) 2.46
PE Ratio 26.74
Forward PE 22.88
Dividend $1.57
Dividend Yield 2.39%

Stock Quote

Trading Day Aug 14, 2020
Last Price $65.77
Previous Close $66.34
Change ($) -0.57
Change (%) -0.86%
Day's Open 65.96
Day's Range 65.57 - 66.22
Day's Volume 499,587
52-Week Range 48.60 - 68.96

More Stats

Market Cap 117.93B
Enterprise Value 114.64B
Earnings Date (est) Oct 30, 2020
Ex-Dividend Date Aug 14, 2020
Shares Outstanding 2.33B
Float 1.66B
EPS (basic) n/a
EPS (diluted) 2.46
FCF / Share 3.31
Dividend $1.57
Dividend Yield 2.39%
Earnings Yield 3.74%
FCF Yield 6.62%
Payout Ratio n/a
Shares Short 2.79M
Short Ratio 2.71
Short % of Float n/a
Beta 0.39
PE Ratio 26.74
Forward PE 22.88
P/FCF Ratio 15.11
PS Ratio 5.86
PB Ratio 15.74
Revenue 20.13B
Operating Income 8.74B
Net Income 6.59B
Free Cash Flow 7.81B
Net Cash 3.30B
Net Cash / Share 1.84
Gross Margin 83.67%
Operating Margin 43.40%
Profit Margin 32.70%
FCF Margin 38.78%
ROA 27.51%
ROE 73.24%
ROIC n/a
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (29)

Buy 13
Overweight 2
Hold 10
Underweight 1
Sell 3

Analyst Consensus: Overweight

Price Target

$70.82*
(7.68% upside)
Low
46.4
Current: $65.77
High
83.5
Target: 70.82
*Average 12-month USD price target from 25 stock analysts.

Financial Performance

Financial numbers in millions DKK.

Financial Overview

Year201920182017201620152014
Revenue122,021111,831111,696111,780107,92788,806
Revenue Growth9.11%0.12%-0.08%3.57%21.53%-
Gross Profit101,93394,21494,06494,59791,73974,244
Operating Income52,48347,24848,96748,43249,44432,952
Net Income38,95138,62838,13037,92534,86026,481
Shares Outstanding2,4502,5002,5502,6002,597-
Earnings Per Share16.3815.9315.3914.9613.5210.07
EPS Growth2.82%3.51%2.87%10.65%34.26%-
Dividend Per Share1.021.051.151.410.560.84
Dividend Growth-2.87%-8.81%-18.78%154.23%-33.85%-
Operating Cash Flow46,78244,61641,16848,31438,28731,692
Capital Expenditures-8,928-9,623-7,617-7,061-5,209-3,986
Free Cash Flow37,85434,99333,55141,25333,07827,706
Cash & Equivalents15,47515,63818,85220,69920,46515,905
Total Debt4,4835151,6942291,073720
Net Cash / Debt10,99215,12317,15820,47019,39215,185
Assets125,612110,769102,35597,53991,79977,062
Liabilities68,01958,93052,54052,27044,83036,768
Book Value57,59351,83949,81545,26946,96940,294
Numbers in millions DKK, except per-share numbers.

Company Profile

Company Details

Full Name Novo Nordisk A/S
Country Denmark
Employees 43,526
CEO Lars Fruergaard Jørgensen

Stock Information

Ticker Symbol NVO
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Biotechnology
Unique Identifier NYSE: NVO

Description

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharmaceuticals. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company has a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. It also has collaboration agreements with Lund University to develop stem cell-derived treatment for Parkinson's diseases; Staten Biotechnology B.V. to develop novel therapeutics for the treatment of dyslipidaemia; Medtronic plc to develop integrated digital solutions for people with diabetes; and bluebird bio, Inc. to develop in vivo genome editing treatments for genetic diseases. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.